Lupin Share Price
(LUPIN)
₹1974
as on 02:14PM, 20 Feb 2025
Lupin Performance
Day's Low
Day's High
₹1,963.8Day's Price Range₹1,996.252 Week's Low
52 Week's High
₹1,493.352-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | -7.15 % |
| 3 Month Return | -3.17 % |
| 1 Year Return | + 24.65 % |
| Market Stats | |
| Previous Close | ₹1,978.25 |
| Open | ₹1,971.90 |
| Volume | 16.51L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹90,303.35Cr |
Lupin Key Statistics
P/E Ratio
31.44
PEG Ratio
1.33
Market Cap
₹90,303.35 Cr
P/B Ratio
3.58
EPS
42.47
Dividend Yield
0.49
Sector
Pharmaceuticals
ROE
11.92
Lupin Mutual Fund Holdings
Lupin Analyst Rating
based on 35 analysts
54.29%
Buy
28.57%
Hold
17.14%
Sell
Based on 35 analysts offering long term price targets for Lupin. An average target of ₹2283.8
Source: S&P Global Market Intelligence
Lupin Share analysis
Lupin price forecast by 35 analysts
Upside of15.45%
High
₹2800
Target
₹2283.80
Low
₹1731
Lupin target price ₹2283.8, a slight upside of 15.45% compared to current price of ₹1974. According to 35 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:34.45%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:108.88%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Lupin Ltd
Lupin Faces Challenges Amid Trade Pressures and Ratings - 19 Feb, 2025
Lupin Ltd is under pressure due to potential U.S. duties on drug exports, impacting earnings estimates. However, it received an 'A-' rating from CDP for sustainability efforts.Lupin Reports Growth in Sales and Profit - 17 Feb, 2025
Lupin's standalone net sales for December 2024 reached Rs 4,208 crore, a 2.24% increase year-over-year. Net profit rose 7.45% to Rs 984.67 crore, while EBITDA increased by 18.21%. However, the stock has seen a -5.02% return over the last six months.Lupin Targets Growth with New Launches and Buy Call - 16 Feb, 2025
Lupin is optimistic about achieving double-digit growth in the US market, supported by a strong product pipeline. Prabhudas Lilladhar has set a buy target of Rs 2,420, suggesting a potential 22.9% upside for investors.Lupin Reports Strong Earnings Amid Market Fluctuations - 14 Feb, 2025
Lupin's management projects strong EBITDA margins for FY25, while analysts maintain buy ratings despite recent share price declines. Revenue and net profit show significant growth.Lupin Reports Strong Q3, Analysts Remain Bullish - 13 Feb, 2025
Lupin's Q3FY25 results surpassed expectations, leading to target price increases from various brokerages. Analysts remain optimistic about the company's growth potential and product pipeline.Lupin Reports Strong Q3 Results Amid Business Restructuring - 12 Feb, 2025
Lupin Ltd reported a 39.5% increase in net profit for Q3 FY25, driven by robust North American sales. Despite a 3% drop in shares, the company announced plans to transfer its OTC healthcare business to a subsidiary, aiming to sharpen its focus on prescription drugs.Lupin Faces Stock Decline Amid FDA Approval - 11 Feb, 2025
On February 11, 2025, Lupin's shares fell despite receiving USFDA approval for Ipratropium Bromide Nasal Solution. The company is set to report Q3 FY25 earnings, with expectations of a net profit of Rs 792.6 crore. However, shares crashed 5% following the news.Lupin Secures Multiple FDA Approvals on February 10 - 10 Feb, 2025
On February 10, 2025, Lupin received FDA approvals for both Bosentan Tablets and Ipratropium Bromide Nasal Solution, strengthening its position in the U.S. market. However, concerns over potential tariffs on pharma imports weighed on the sector.Lupin Ltd Shares Rise Ahead of Earnings Announcement - 09 Feb, 2025
Lupin Limited's shares closed at Rs 2,213, reflecting a 1.22% increase. The company, with a market cap of Rs 1.01 lakh crore, will announce results on February 11, 2025.Lupin Faces Penalty Amid Positive Stock Momentum - 06 Feb, 2025
Lupin Limited is facing a ₹2.28 crore penalty from West Bengal GST authority for ITC misuse, while its stock shows bullish momentum and consolidation patterns, indicating potential upward movement.Lupin Gains FDA Approval Amid Penalty News - 03 Feb, 2025
Lupin's Somerset facility successfully passed a US FDA inspection, and the company received approval for a generic HIV medication. However, it faces a Rs 3.55 crore penalty from the Maharashtra GST Authority for alleged wrongful ITC claims.Budget Measures Expected to Benefit Lupin Ltd - 01 Feb, 2025
Following the budget announcement, pharmaceutical stocks, including Lupin, are expected to remain in focus due to critical tariff changes that could boost the sector.Lupin's Strong Performance and Growth in 2024 - 29 Jan, 2025
Lupin's share price surged 77% in 2024, outperforming the NIFTY Pharma index. The company reported 10% sales and 17% profit CAGR over three years, with FII ownership rising from 16.11% to 22.06%.Lupin Launches NaMuscla® in Italy Amid Market Decline - 28 Jan, 2025
Lupin Limited, in collaboration with Avas Pharmaceuticals, launched NaMuscla® in Italy, the first licensed treatment for myotonia in adults. However, shares of Lupin fell as the Nifty Pharma index dropped nearly 3% on the same day.Lupin Secures FDA Approvals for Key Medications - 24 Jan, 2025
Lupin has received FDA approval for its heart failure therapy and tentative approval for a pediatric HIV medication, enhancing its product portfolio significantly.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 21.50% to 22.04% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.89% to 16.92% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 35.2%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.96% to 46.95% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.44% to 6.26% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, LUPIN stock has moved down by -7.2%
Lupin Financials
Index Inclusions
Lupin Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.95% | ||
| Foreign Institutions | 22.04% | 2.52 | |
| Mutual Funds | 16.92% | 0.20 | |
| Retail Investors | 6.26% | ||
| Others | 7.82% |
Lupin Key Indicators
Lupin Valuation
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (31.44x)
February 19, 2025
Industry (51.87x)
February 19, 2025
Highest (517.33x)
December 2, 2022
Lupin Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.61%.
Read More about Dividends
Lupin Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bearish trading position according to technical analysis indicators.
Lupin Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹90,303.35 Cr | 36.55% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹12,048.61 Cr | -5.69% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹66,515.75 Cr | 17.86% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹89,700.73 Cr | 43.85% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹63,157.44 Cr | 18.28% | 0.53 | NA | NA |
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Share Price: ₹1974.00 per share as on 20 Feb, 2025 02:14 PM
Market Capitalisation: ₹90,303.35Cr as of today
Revenue: ₹5,618.56Cr as on December 2024 (Q4 24)
Net Profit: ₹858.86Cr as on December 2024 (Q4 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Lupin Ltd
What is Lupin Ltd price today?
Lupin Ltd share price today stands at ₹1974, Open: ₹1971.9, Previous Close: ₹1978.25, High: ₹1996.2, Low: ₹1963.8, 52 Week High: ₹2402.9, 52 Week Low: ₹1493.3.
How to Buy Lupin Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Lupin Ltd shares
Is Lupin Ltd listed on NSE?
Lupin Ltd is listed on NSE
Is Lupin Ltd listed on BSE?
Lupin Ltd is listed on BSE
What are today's High and Low prices of Lupin Ltd?
- Today's highest price of Lupin Ltd is ₹1996.2.
- Today's lowest price of Lupin Ltd is ₹1963.8.
What are today's traded volumes of Lupin Ltd?
Today's traded volume of Lupin Ltd(LUPIN) is 16.51L.
What is today's market capitalisation of Lupin Ltd?
Today's market capitalisation of Lupin Ltd(LUPIN) is ₹90303.35Cr.
What is the 52 Week High and Low Range of Lupin Ltd?
How much percentage Lupin Ltd is down from its 52 Week High?
Lupin Ltd (LUPIN) share price is ₹1974. It is down -17.85% from its 52 Week High price of ₹2402.9
How much percentage Lupin Ltd is up from its 52 Week low?
Lupin Ltd (LUPIN) share price is ₹1974. It is up 32.19% from its 52 Week Low price of ₹1493.3
What are the historical returns of Lupin Ltd?
What is the PE ratio of Lupin Ltd today?
PE Ratio of Lupin Ltd is 31.44
PE ratio = Lupin Ltd Market price per share / Lupin Ltd Earnings per share